The activities and regulatory landscape of cellular therapies including hematopoietic cell transplantation in the world

Blood Cell Ther. 2022 Dec 23;5(Spec Edition):S15-S24. doi: 10.31547/bct-2022-013. eCollection 2022 Dec 23.

ABSTRACT

A variety of cellular therapies including hematopoietic cell transplantation (HCT) hold the promise to treat medical conditions and diseases that currently have limited or no effective therapeutic options. A number of cellular therapies other than HCT, such as CAR T-cell therapy, are currently in preclinical and clinical development and the field is rapidly growing. The current activity of cellular therapies, including HCT, in the clinical setting are summarized in this article. Collaborative efforts from all relevant professionals and organizations will be of great importance to overcome substantial challenges in clinical development and post-launch evidence collection of cellular therapies. Harmonization among decision-makers also plays a critical role in reinforcing consistency and improving efficiencies of the regulatory and health technology assessment process. For the long-term safety follow-up of patients undergoing cellular therapies, registries for HCT are able to manage the complexity of data and in the best position to introduce and monitor future innovative cellular therapies for a variety of hematological disorders.

PMID:37220608 | PMC:PMC10200362 | DOI:10.31547/bct-2022-013